Alomfilimab

艾洛利单抗

Report date: 2024/10/17 20:00:06

Base Information

Drug NameAlomfilimab
Drug Alias NameKY-1044SAR-445256
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInducible T-cell costimulator agonists
TargetsInducible T-cell costimulator
Therapy Area/IndicationsNeoplasm MetastasisUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanPoland +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKymab Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKymab Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[12] 

Other Information

ATC CodeN/A
Related LinksN/A